1. Home
  2. MLEC vs AKTX Comparison

MLEC vs AKTX Comparison

Compare MLEC & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Moolec Science SA

MLEC

Moolec Science SA

HOLD

Current Price

$9.41

Market Cap

4.7M

Sector

Finance

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$0.25

Market Cap

11.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLEC
AKTX
Founded
2008
N/A
Country
Cayman Islands
United States
Employees
N/A
12
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7M
11.3M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
MLEC
AKTX
Price
$9.41
$0.25
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$2.53
AVG Volume (30 Days)
2.0M
192.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$20.42
N/A
Revenue Next Year
$30.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.21
$0.22
52 Week High
$23.22
$1.72

Technical Indicators

Market Signals
Indicator
MLEC
AKTX
Relative Strength Index (RSI) 47.66 50.28
Support Level $1.52 $0.25
Resistance Level $12.96 $0.27
Average True Range (ATR) 3.36 0.02
MACD -0.78 0.00
Stochastic Oscillator 9.27 50.94

Price Performance

Historical Comparison
MLEC
AKTX

About MLEC Moolec Science SA

Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline, such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's maximum revenues from operations in Argentina.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

Share on Social Networks: